Jonathan Lynn Lavezo, MD
Pathology · El Paso
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 11 years
- Graduated 2015
Offices
1 location · Texas Tech University Health Sciences Center El Paso · 306 clinicians in this group
Hospitals listed: The Hospitals of Providence Transmountain Campus · University Medical Center of El Paso. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lavezo’s office at (915) 215-4956 to ask if they take your plan before you enroll.
State licence records
1 licence
- Texas S6875Physician License · since 2020 · expires 2027-05-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- The Hospitals of Providence Transmountain CampusEl Paso, TXAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 64% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025
- University Medical Center of El PasoEl Paso, TXAcute Care Hospital · Physician · Has an emergency department · Birthing-friendlyPart of El Paso County Hospital DistrictPatients rate it 3 of 5 · 71% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.58 (0.78 to 2.39) · 2,319 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.441, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.142, Oct 2024 – Sep 2025
See every measure and the patient survey for The Hospitals of Providence Transmountain Campus
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.01) · 406 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.6 to 1.48) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart attack patientsComplications and deaths | 12.9 · 33 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.8 · 99 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 71 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 1,626 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,849 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.08 to 0.51) · 1,903 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.94 (1.48 to 6.41) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.48 (0.81 to 4.15) · 297 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.24) · 94 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.7 (0 to 1.66) · 1,507 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 75 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 84 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 276 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17 · 117 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 15.6 · 190 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 19.2) · 182 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 197 cases | No different | Jan 2024 – Dec 2024 |
What patients said (731 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 4 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 76% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 64% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for University Medical Center of El Paso
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.58 (0.78 to 2.39) · 2,319 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.441 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.142 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.96) · 518 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.31 (0.91 to 1.7) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.74 (147 to 250.49) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 31 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.7 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 364 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.7 · 2,719 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,497 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.12 to 0.54) · 2,339 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.71 (1.45 to 5.97) · 699 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.35) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.48 (0.9 to 4.06) · 719 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.75 (1.22 to 20.28) · 92 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.89 (0.69 to 9.09) · 104 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 119 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.686 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.879 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.737 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.44 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.7 · 168 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 331 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -36.2 · 69 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 71 · 104 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 338 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.2 (4 to 9.8) · 27 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.4 to 15.9) · 27 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.4) · 360 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 97 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,426 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 71% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$14,956
Medicare paid this office $14,956 for 161 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Pathology examination of tissue using a microscope, intermediate complexity | 110 | $5,969 | $24 |
| Special stained specimen slides to examine tissue, each additional procedure | 23 | $2,254 | $21 |
| Pathology examination of tissue using a microscope, moderately high complexity | 26 | $2,117 | $59 |
| Special stained specimen slides to identify organisms including interpretation and report | 38 | $1,185 | $19 |
| Special stained specimen slides to examine tissue, initial procedure | 30 | $879 | $26 |
See all 7 services
| Pathology examination of tissue using a microscope, intermediate complexity | 110 | $5,969 | $24 |
| Special stained specimen slides to examine tissue, each additional procedure | 23 | $2,254 | $21 |
| Pathology examination of tissue using a microscope, moderately high complexity | 26 | $2,117 | $59 |
| Special stained specimen slides to identify organisms including interpretation and report | 38 | $1,185 | $19 |
| Special stained specimen slides to examine tissue, initial procedure | 30 | $879 | $26 |
| Cell examination of specimen, selective cellular enhancement technique | 11 | $204 | $19 |
| Pathology examination of tissue using a microscope, moderately low complexity | 17 | $168 | $8 |
Who their Medicare patients are
161 Original Medicare patients in 2024. Average age 72 · Under 65 12% · 85 and older 11% · Women 56% · Also on Medicaid 19% · Health risk score 1.80. Above the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: High blood pressure 75% · Diabetes 46% · Chronic kidney disease 32% · Coronary heart disease 25% · Cancer 22% · Depression 21% · Atrial fibrillation 17% · Heart failure 16% · COPD 16% · Stroke 14% · Dementia 11%.
The office billed $55,988, Medicare allowed $19,894 and paid $14,956; for 604 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 161 | 604 | 72 | 1.80 | $55,988 | $14,956 |
| 2023 | 171 | 644 | 71 | 1.70 | $62,660 | $16,427 |
| 2022 | 160 | 596 | 70 | 1.40 | $59,251 | $16,086 |
| 2021 | 196 | 773 | 69 | 1.69 | $74,027 | $20,951 |
| 2020 | 54 | 173 | 72 | 1.72 | $15,175 | $4,785 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Pathology examination of tissue using a microscope, intermediate complexity | 106 | $5,682 | $26 |
| Special stained specimen slides to examine tissue, each additional procedure | 27 | $3,379 | $21 |
| Pathology examination of tissue using a microscope, moderately high complexity | 26 | $2,388 | $61 |
| Special stained specimen slides to identify organisms including interpretation and report | 31 | $1,074 | $20 |
| Special stained specimen slides to examine tissue, initial procedure | 31 | $872 | $25 |
| Cell examination of specimen, selective cellular enhancement technique | 15 | $292 | $19 |
| Pathology examination of tissue using a microscope, moderately low complexity | 29 | $253 | $8 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $164 | $9 |
2022: 6 services
| Pathology examination of tissue using a microscope, intermediate complexity | 96 | $5,408 | $28 |
| Special stained specimen slides to examine tissue, each additional procedure | 27 | $3,230 | $21 |
| Pathology examination of tissue using a microscope, moderately high complexity | 26 | $2,544 | $64 |
| Special stained specimen slides to examine tissue, initial procedure | 28 | $778 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 26 | $672 | $20 |
| Pathology examination of tissue using a microscope, moderately low complexity | 33 | $386 | $9 |
2021: 11 services
| Pathology examination of tissue using a microscope, intermediate complexity | 128 | $7,254 | $28 |
| Special stained specimen slides to examine tissue, each additional procedure | 32 | $3,561 | $22 |
| Pathology examination of tissue using a microscope, moderately high complexity | 24 | $2,547 | $62 |
| Special stained specimen slides to identify organisms including interpretation and report | 53 | $1,597 | $21 |
| Special stained specimen slides to examine tissue, initial procedure | 39 | $1,357 | $27 |
| Evaluation of fine needle aspirate with interpretation and report | 13 | $809 | $54 |
| Evaluation of fine needle aspirate | 13 | $395 | $26 |
| Pathology examination of tissue using a microscope, moderately low complexity | 37 | $368 | $9 |
| Special stained specimen slides to examine tissue including interpretation and report | 11 | $191 | $10 |
| Preparation of tissue for examination by removing any calcium present | 11 | $98 | $9 |
| Pathology examination of tissue using a microscope, limited examination | 13 | $42 | $3 |
2020: 2 services
| Pathology examination of tissue using a microscope, intermediate complexity | 35 | $2,070 | $30 |
| Special stained specimen slides to identify organisms including interpretation and report | 17 | $545 | $22 |
Medicaid work
$1,420 in 2024
Medicaid paid $1,420 for 30 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 30 | $1,420 |
| 2024 | 30 | 1 | 16 | $1,420 |
| 2023 | 88 | 1 | 21 | $3,800 |
| 2022 | 106 | 1 | 17 | $4,330 |
| 2021 | 179 | 1 | 25 | $7,628 |
| 2020 | 31 | 1 | 16 | $1,416 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 88 | $3,800 |
2022
| TISSUE EXAM BY PATHOLOGIST | 106 | $4,330 |
2021
| TISSUE EXAM BY PATHOLOGIST | 179 | $7,628 |
2020
| TISSUE EXAM BY PATHOLOGIST | 31 | $1,416 |
Money from drug and device companies
$89 in 2025
| 2025 | 3 | 4 | None | $89 |
| 2024 | 3 | 3 | None | $53 |
| 2023 | 1 | 1 | None | $19 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Tagrisso | $37 | 2 payments
|
| Gilead Sciences | Trodelvy | $30 | 1 payment
|
| Janssen Biotech | Rybrevant | $22 | 1 payment
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-30 | None | $21 |
| Janssen Biotech | Meals · 2025-07-29 | Rybrevant | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-25 | Tagrisso | $16 |
| Gilead Sciences | Meals · 2025-01-07 | Trodelvy | $30 |
See earlier years (2024, 2023)
2024: $53
| Daiichi Sankyo | Enhertu | $23 | 1 payment
|
| Tempus AI | None | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $13 | 1 payment
|
2023: $19
| Tolmar | Eligard | $19 | 1 payment
|
Professional record
- NPI
- 1518352640
- Licence
- TX S6875Texas S6875: Active
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZN0500X (207ZN0500X); Student in a training program (390200000X)
- Mailing address
- 5130 Gateway Blvd E # 51015, El Paso, TX, 79905
- NPI first listed
- 2015-04-06
- NPI last updated
- 2023-11-08
- NPI record certified
- 2023-11-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305